Page last updated: 2024-10-24

1-o-hexadecyl-2-n-methylcarbamylphosphatidylcholine and Leukemia, Erythroblastic, Acute

1-o-hexadecyl-2-n-methylcarbamylphosphatidylcholine has been researched along with Leukemia, Erythroblastic, Acute in 1 studies

1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine: biologically active analog of PAF; structure given in first source

Leukemia, Erythroblastic, Acute: A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.

Research Excerpts

ExcerptRelevanceReference
"Using murine erythroleukemia cells (MELCs) as the model, we found that WEB-2086, a triazolobenzodiazepine-derived PAF antagonist originally developed as an anti-inflammatory drug, induces a dose-dependent inhibition of MELC growth and hemoglobin accumulation as a result of a true commitment to differentiation."1.31Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells. ( Bianchi, L; Cellai, C; Della Malva, N; Laurenzana, A; Paoletti, F; Vannucchi, AM, 2002)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cellai, C1
Laurenzana, A1
Vannucchi, AM1
Della Malva, N1
Bianchi, L1
Paoletti, F1

Other Studies

1 other study available for 1-o-hexadecyl-2-n-methylcarbamylphosphatidylcholine and Leukemia, Erythroblastic, Acute

ArticleYear
Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2002, Volume: 16, Issue:7

    Topics: Animals; Antineoplastic Agents; Azepines; Cell Differentiation; Cell Division; Dose-Response Relatio

2002